Assuming an increase in median OS of 4 months with RE versus sorafenib therapy , randomising at least 400 patients ( 200 in each treatment arm ) will be sufficient for 80 % power and a bilateral alpha risk of 5 % ; therefore , 440 patients will be enrolled to allow for 10 % loss of patients due to ineligibility .